A subsequent trial study showed that the combined use of the inhibitors of BRAF (dabrafenib), EGFR (panitumumab), and MEK (trametinib) provided treatment benefits in patients with BRAFV600E CRC [142]. Here, BRAF is linked to colorectal carcinoma.